Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
OPEN Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | 26 Feb 2015
CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, FB Hagemeister, RE Champlin and ML Wang
Although ibrutinib is highly effective in patients with relapsed/refractory mantle cell lymphoma (MCL), a substantial proportion of patients have resistant disease. The subsequent outcomes of such patients are unknown.
* Data courtesy of Altmetric.com